2023年6月6日

植物使癌症药物包括阿瓦斯丁和赫赛汀,以及Actemra风湿性关节炎。在大流行期间,罗氏与Regeneron药品增加供应制药商的COVID-19抗体治疗。路透|更新:06-06-2023是06:00时|创建:06-06-2023 06:00时坚持分享瑞士制药公司罗氏计划出售其拥有800名雇员的药品生产工厂在维尔市,加利福尼亚,或将关闭工厂,到2029年,根据邮件给工人被路透社周三。罗氏公司在一份声明中证实了剥离计划网站,这使得从转基因活细胞单克隆抗体,但没有解决潜在的关闭工厂或其时间表。该公司在声明中说,希望不需要工厂提供的大量药物,和大规模生产将会在一个公司的新植物。它还计划关注药物针对较小的患者人群向前移动,利用一系列的生物技术方法除了单克隆抗体,它补充说,不会影响操作或员工。罗氏是今年新领导下首席执行官托马斯Schinecker掌舵和特蕾莎•格雷厄姆成为制药部门负责人3月。瑞士集团是在压力下开发新的治疗方法来抵消损失数十亿美元的销售由于廉价的生物技术份建立癌症药物赫赛汀,阿瓦斯丁和利妥昔单抗,其中一些是由维尔市。它也与浸渍收入竞争COVID-19疗法和测试。该公司表示,它正在寻找买家,将继续使用植物作为操作设备。 If the company is unable to find a buyer, it will ramp down production and close the plant in 2028 to 2029, the emails said. Roche acquired the plant more than a decade ago with its purchase of U.S. biotech Genentech. The plant makes drugs for cancer including Avastin and Herceptin, as well as Actemra for rheumatoid arthritis. During the pandemic, Roche collaborated with Regeneron Pharmaceuticals to increase supply of that drugmaker's COVID-19 antibody treatment. Roche manufactured the treatment at the Vacaville plant, which it sells outside the U.S. under the brand name Ronapreve. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) Advertisement